Creator of COVAX-19: Professor Nikolai Petrovsky

Professor Nikolai Petrovsky is the Director of Endocrinology at Flinders Medical Centre with a conjoint position as Professor of Medicine at Flinders University. He is Vice-President and Secretary-General of the International Immunomics Society. Nikolai is the founder of Vaxine, a company funded by the US National Institutes of Health to develop novel vaccine technologies. in 2009 Vaxine won the Amp Innovation Award at the Telstra Business Awards and Australia's Coolest Company award from Australian Anthill Magazine. During his career Nikolai has developed vaccines against influenza, hepatitis b, sting allergy, malaria, Japanese Encephalitis, rabies and HIV, and has authored over 90 papers and academic chapters. ------------------------------------------ Watch this episode on Youtube: https://youtu.be/42Z2rztT_Es Nikolai’s company Vaxine which developed COVAX-19: https://vaxine.net/ ------------------------------------------ 00:11 Summary of interview 04:00 Zoom starts 05:30 Vaccines can treat almost anything 07:55 How vaccines work against non-infectious diseases 09:40 Human bio engineering and evolution 11:47 Experimental vaccine rollout worldwide 16:07 Making vaccines mandatory is highly inappropriate right now 18:21 Are the mRNA vaccines a true vaccine or simply a ‘therapy’? 19:54 Vaxine has developed a much safer vaccine called COVAX-19 23:52 The side effect profiles of mRNA and viral vector vaccines (Pfizer and AstraZeneca) 28:35 Adjuvents in vaccines like aluminium 29:44 When will COVAX-19 be available? 33:14 Other companies making ‘protein’ vaccines 34:05 Sterilising immunity (preventing infection) vs reducing symptoms 35:20 How influenza vaccines will improve 36:27 The eradication of influenza 37:46 Why does social distancing, masks etc prevent Influenza but not COVID-19? 40:23 Cross reactivity between influenza and COVID-19 42:43 Getting a vaccine is better than the getting the infection 46:18 mRNA vaccines are being used to lessen symptoms, not prevent infectivity 48:35 Legal indemnity for vaccine developers